Physician profile
Ethan Sobol
NPI 1922530336
$2,263.91
in general payments reported to CMS, 2019-2025
13 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $151 · 2023: $359 · 2024: $672 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.77 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $460.44 | 2023-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $261.46 | 2024-2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $255.43 | 2025 | Syfovre |
| Dutch Ophthalmic, USA | $239.27 | 2022-2023 | Eva, Combined Machine, Tissueblue |
| Alcon Vision LLC | $214.78 | 2021 | |
| Abbvie INC. | $186.90 | 2023-2025 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Bausch & Lomb Americas INC. | $123.10 | 2024 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $116.16 | 2025 | |
| Oyster Point Pharma, INC. | $95.24 | 2023 | Tyrvaya |
| Astellas Pharma US INC | $94.11 | 2024-2025 | Izervay |
| Ocular Therapeutix, INC. | $39.27 | 2025 | Dextenza |
| Genentech, INC. | $27.75 | 2024 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.